Answers are grounded in this paper and cite their sources.
Etirinotecan pegol showed substantial antitumor activity in patients with various solid tumors and a somewhat different safety profile compared with the irinotecan historical profile. The MTD recommended for phase II clinical trials is 145 mg/m(2) q14d or q21d.
No takes yet. Share an insight, caveat, or question.
Jameson et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: